secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2025-09-30T23:59:59+00:00
Accession:  0001104659-25-094758
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix prices $475M common stock offering at $12.53/share to fund AXPAXLI trials
--------------------------------------------------------------------------------

- Offering of 37,909,018 shares priced at $12.53 each for gross proceeds ~$475M; net proceeds ~$445.9M.
- Net proceeds plus existing cash expected to fund operations into 2028, excluding full AXPAXLI commercial launch costs.
- Funds to support AXPAXLI open-label extension in wet AMD, Phase 3 trials in NPDR, and manufacturing scale-up.
- Offering expected to close Oct 1, 2025; BofA Securities, TD Cowen, Piper Sandler & Co. acting as joint book-runners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465925094758/0001104659-25-094758-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465925094758/tm2527344d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-094758

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer